<DOC>
	<DOCNO>NCT00970957</DOCNO>
	<brief_summary>Lack effective treatment macular edema secondary central retinal vein occlusion bad response grid laser treatment patient macular edema secondary branch retinal vein occlusion , together high incidence pathology great functional loss patient suffer motivate search new therapeutic approach . In recent time , intravitreal bevacizumab test clinical practice small series patient pathology , whether first treatment failure grid laser treatment good functional result short series . However , retreatment information available , although preliminary result publish series good .</brief_summary>
	<brief_title>Safety Effectiveness Bevacizumab Intravitreal Injections Treatment Macular Edema Secondary Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patient male female 18 year old Foveal macular edema secondary Retinal Vein Occlusion confirm Fluorescein angiography Optical Coherence Tomography , subcentral field thickness least 250 micron Patients best correct visual acuity loss within last 6 month evolution , cause macular edema state investigator´s judgement . Best correct visual acuity test ETDRS within 20/40 20/400 study eye . Signed Informed consent . Signed Data Protection Consent . Negative pregnancy test enter study childbearing potential woman , must commit use medically accept contraceptive method whole study . Macular Subcentral field assess Ocular coherence tomography least 250 micron thick . No presence eye opacity may prevent fundus exploration . No condition may prevent correct eye dilation . No known allergy fluorescein . Only eye per patient include study , even eye pathology . Macular edema secondary condition : diabetes retinopathy , hypertension , Juxtafoveal telangiectasia , ... Any previous treatment macular edema photocoagulation , vitrectomy , triamcinolone , radial optic neurotomy , ... study eye . Any ocular illness thay may associate increased/high level VEGF ( Age relate macular degeneration , Diabetes retinopathy , Uveitis , ... ) Systemical illness thay may associate increased/high level VEGF ( e.g . tumour ) . Medical history brain vascular episode ( stroke ) , ictus , angor pectoris myocardial infarct within 3 month study inclusion . Pregnancy nursing . Hypersensibility know suspect Bevacizumab , excipients related molecule . Uncontrolled hypertension refractary medical treatment . Participation trial study within last 3 month ( mineral vitamin exclude ) treatment antiVEGF nonstudy eye within previous 3 month . Tractional maculopathy and/or epiretinal membrane assess Ocular Coherence Tomography . Media opacities don´t allow correct eye exploration fundus examination/photographs . Cataract surgery / Yag capsulotomy within previous 6 month . Filtration surgery . Previous medical history ocular illness : viral infection , inflammatory pathology , serous central choroidopathy , retinal detachment illness may influence visual acuity . Presence foveal atrophy , severe pigmentary change , dense subfoveal haemorrhage , confluent subfoveal hard exudate condition may influence functional recovery macular edema . Cataract may responsible additional visual acuity loss 2/10 . Medically uncontrolled intraocular pressure high 25 mm Hg . External ocular illness active inclusion : conjunctivitis , blepharitis , eye sore , ...</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Macular edema</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>